NTRK2 and primary ovarian failure: TrkB-agonist antibodies such as Ab4B19 have demonstrated the ability to penetrate ovarian follicles after intravenous administration in mice, activate TrkB signaling, restore folliculogenesis, and normalize gonadal hormone levels in models of premature ovarian failure and aging.